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Abstract: The most common animal models currently used for Alzheimer disease (AD) research are transgenic mice that 
express a mutant form of human A precursor protein (APP) and/or some of the enzymes implicated in their metabolic 
processing. However, these transgenic mice carry their own APP and APP-processing enzymes, which may interfere in 
the production of different amyloid-beta (A) peptides encoded by the human transgenes. Additionally, the genetic back-
grounds of the different transgenic mice are a possible confounding factor with regard to crucial aspects of AD that they 
may (or may not) reproduce. Thus, although the usefulness of transgenic mice is undisputed, we hypothesized that addi-
tional relevant information on the physiopathology of AD could be obtained from other natural non-transgenic models. 
We have analyzed the chick embryo and the dog, which may be better experimental models because their enzymatic ma-
chinery for processing APP is almost identical to that of humans. The chick embryo is extremely easy to access and ma-
nipulate. It could be an advantageous natural model in which to study the cell biology and developmental function of APP 
and a potential assay system for drugs that regulate APP processing. The dog suffers from an age-related syndrome of 
cognitive dysfunction that naturally reproduces key aspects of AD including A cortical pathology, neuronal degeneration 
and learning and memory disabilities. However, dense core neuritic plaques and neurofibrillary tangles have not been 
consistently demonstrated in the dog. Thus, these species may be natural models with which to study the biology of AD, 
and could also serve as assay systems for A-targeted drugs or new therapeutic strategies against this devastating disease. 
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INTRODUCTION 
  The ethics of scientific research obliges to reduce the use 
of laboratory animals to the minimum possible. Neverthe-
less, studies in animal models are still necessary to under-
stand the mechanisms of many human diseases and to try 
new therapeutic strategies. In any case, experiments with 
animals must always be approved by ethical committees and 
to enforce general and local normatives (see for example 
European and Spanish legislations on animal handling 
86/609/EU and Real Decreto 1201/2005, respectively). 
  Rodents in general, and the rat and the mouse in particu-
lar, are the animals most frequently used as experimental 
model organisms for a great variety of human diseases. The 
short reproductive cycle of these small mammals (21 days of 
gestation), their high birth rate, and their small size make 
them relatively easy to maintain and manage. Recent devel-
opments in genetic engineering and biotechnology have led 
to the production of a diverse selection of transgenic ani-
mals, mainly mice. These transgenic animals (bearing an 
exogenous gene, usually from human origin), together with 
other agenics or knockouts (in which a particular gene has 
been blocked or eliminated) have been very useful in study-
ing the presumptive roles and mechanisms involving the 
proteins coded by the transgene or the knockout gene of in-
terest. Translational research has brought particular these 
technologies to the field of clinical investigation, with the 
production of inbred animal lines that serve as models for 
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human diseases. Numerous knockout and transgenic animal 
models have been developed to explore particular aspects of 
Alzheimer’s disease.  
  Suppression of genes that encode proteins involved in 
Alzheimer’s, such as APP, apolipoprotein E (ApoE), -
secretase, or presenilins, has helped us to anticipate the ef-
fects of presumptive new molecules designed to regulate 
these proteins. For example, presenilin knockout mice  de-
velop striking neurodegeneration of the cerebral cortex and 
worsening impairments of memory and synaptic function 
with increasing age, which call for caution in the therapeutic 
use of -secretase inhibitors [1]. In contrast, -secretase 
knockout mice are perfectly viable [2]. The absence of lethal 
phenotypes for -secretase knockouts, which cannot generate 
A peptide, feeds the hope of success for therapeutic strate-
gies based on the use of -secretase inhibitors or aimed di-
rectly at the blockade or elimination of A peptide. Never-
theless, APP knockout mice present overt neurological defi-
ciencies which can be reverted if the endogenous APP locus 
is replaced by a gene-targeted allele (knock-in mice) that 
exclusively express the secreted APP ectodomain [3, 4]. In 
addition, functional redundancy between APP and other 
APP-like proteins has been reported [5]. The development of 
transgenic mice lines with mutated human APP genes has 
been particularly enlightening, since these animals develop 
A deposits in their brains and reproduce some of the neuro-
logical symptoms of AD. However, most of these species 
lack essential features of AD despite the increasingly com-
plex genotypes that are being engineered to approach a more 
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different transgenics should be considered a possible con-
founding factor that seeds doubts when observations made in 
humans must be interpreted in the light of results obtained in 
these models. Uncertainty is also unavoidable when the effi-
cacy of new AD therapies must be forecasted from trials in 
transgenic mice. 
  Thus, although the usefulness of transgenic mice is un-
disputed, we hypothesized that additional relevant informa-
tion regarding the pathological mechanisms of AD could be 
obtained from natural non-transgenic models. In the follow-
ing pages we will refer to some of the results obtained in our 
laboratory that led us to propose new wild type animal mod-
els for the analysis of relevant aspects of AD. We have de-
signed and produced highly specific and sensitive antibodies 
against the two major isoforms of the A amyloid to aid in 
this research, and are currently exploring the use of these A 
immunogens in the search for premorbid biomarkers and 
immunotherapeutic strategies.  
THE RAT 
  The rat is the most frequently utilized experimental ani-
mal in neuroscience, although with regard to AD the use of 
transgenic mice has been increasing. Nevertheless, an enor-
mous amount of work has been produced in the rat, and im-
portant advances in the understanding of APP processing— 
including the studies central to the discovery of neprilysin 
[15] and insulin degrading enzyme (IDE) [16] as the main 
proteases implicated in A degradation— have been ob-
tained from experiments conducted in rats. The rat has also 
been used to study the effects of induced cortical A accu-
mulation on the cholinergic, noradrenergic, and serotonergic 
systems [17], as well as the influence of diet and age on the 
effects of intracerebral beta-amyloid injection [18]. How-
ever, it should be emphasized that the primary structures of 
the A peptide in rats (and mice) differ from their human 
counterpart at three amino acid residues, and that the com-
plete A-peptide profile produced by the processing of APP 
in these rodents’ also reveals major differences compared to 
that of humans [19]. 
  In our laboratory, the rat was chosen to study the kinetics 
of the expression of the different APP isoforms in response 
to axotomy [20]. We found increased levels of APP 695, 
714, 751, and 770 mRNAs after facial or hypoglossal nerve 
axotomy of the parent ipsilateral motor neurons. The in-
crease was gradual, reaching maximal values 7 days after 
axotomy, and returning to normal values by 60 days after the 
lesion. Increased APP immunostaining was also detected in 
the chromatolytic motor neurons, but not in the reactive as-
trocytes surrounding axotomized neurons. These results sug-
gested a possible neuroprotective role for APP that could 
also be involved in a variety of cell processes that remain 
poorly understood [21-23]. In particular, APP has been im-
plicated in neurotrophic,
  synaptogenic, and growth-
promoting mechanisms which led us to investigate the ex-
pression of this protein during the rat embryogenesis [24]. 
Using oligonucleotides recognizing each of the four major 
APP (APP-695, APP-714, APP-751, and APP-770) mRNAs, 
we found that each APP displays a specific temporal and 
spatial expression pattern. The prototype isoform APP-695 
appears early in embryogenesis within cells actively impli-
cated in morphogenetic events, such as the mesodermal cells 
that invaginate at the level of the primitive streak, and is later 
restricted to the neurectodermal derivatives (neural tube, 
neural crest, and neurogenic placode). By contrast, expres-
sion of the longest isoform, APP-770, occurs later and is 
restricted to mesodermal and endodermal derivatives. The 
isoforms of 714 and 751 amino acids are expressed still later 
in the course of prenatal development, and appear to be dis-
tributed ubiquitously. 
  Another wild type rodent used for research in AD is the 
guinea pig [25]. Beta-amyloid peptide sequence expressed 
by guinea pigs is identical to the human sequence, and ap-
pears to represent a more physiological model with which to 
examine in vivo the long-term effects of experimental ma-
nipulations on APP processing. Additionally, APP process-
ing in guinea pig primary neuronal cultures is demonstrably 
similar to analogous cultures of human origin [25]. However, 
the use of these animals is limited because they do not de-
velop the pathological features of the disease (senile plaques 
and neurofibrillary tangles) and there are not well-
established behavioral tests for this species. 
THE RABBIT 
  As in guinea pigs, the rabbit A peptide sequence is iden-
tical to human [26] and does not present AD pathology spon-
taneously. However, when copper is added to the diet of cho-
lesterol-fed rabbits, they develop cortical amyloid deposits 
and up to twelve other pathological markers seen in AD, 
including retardation of the ability to learn a difficult task 
[27]. This finding suggests that copper (but apparently not 
other heavy metals like aluminum or zinc) may influence the 
progression of Alzheimer's disease by reducing clearance of 
A from the brain [28, 29]. This finding also emphasized the 
usefulness of the rabbit model, whose validity is being ex-
tended even to treatment modalities [30-32]. 
THE CHICK EMBRYO 
  Our studies regarding the prenatal expression of different 
APPs in the rat embryo [24] were coincident in time with the 
publication of reports on the lack of substantial phenotypic 
differences in APP knockout mice [5]. This led us to explore 
the chick embryo as a possible model for the investigation of 
presumptive APP functions during prenatal development. 
The chick embryo is readily available and easy to work with, 
and our laboratory has extensive experience with this model. 
Before engaging in experiments on the functional blocking 
of APP, we first needed to know the sequence of the APP 
gene in the chicken. We isolated the total RNA from the 
chick embryo and cloned the cDNA [33]. We found two of 
the major APP isoforms, APP-751, which contains the KPI 
domain, and APP-695. The APP-770 isoform, which is the 
longest isoform and contains the OX-2 domain, was absent 
or minimally expressed. Interestingly, the chick and human 
gene sequences are almost identical, with 93% amino acid 
identity and 96% similarity. The KPI domain of APP-751 
has 52 identical residues out of 56 (93% identity), and three 
of the four different residues belong to the same group of 
amino acids (98% similarity). The 40–42 amino acid resi-
dues of the A domain are identical, as are the last 101 C-
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the A, transmembrane and intracytoplasmic domains). We 
also established through whole-mount in situ hybridization 
histochemistry and immunohistochemistry
1 that chicken APP 
expression parallels mammalian APP expression both tem-
porally and topographically [32]. After the 3
rd day of embry-
onic development, APP-695 mRNA expression levels were 
much higher than APP-751 expression levels in the neuroec-
todermal derivatives, including the neural tube; the sensory, 
autonomic and cranial ganglia; the retina; and the otic vesi-
cle. Furthermore, the chick embryo expresses the genes that 
encode the main proteases implicated in the production of 
beta amyloid protein, including BACE-1, BACE-2, preseni-
lin-1, presenilin-2, and nicastrin; A1-42 is the major A 
peptide produced during chick embryogenesis [33]. Ne-
prilysin, the main A-degrading enzyme, and ADAM-17, a 
protease implicated in the non-amyloidogenic processing of 
APP, are also expressed in chick embryos. Thus, we propose 
the chick embryo as a suitable natural model in which to 
study the cell biology and developmental function of beta-
amyloid precursor protein, and a potential assay system for 
drugs that regulate beta-amyloid precursor protein process-
ing. But do chicks suffer any Alzheimer-like pathology? We 
have explored whether relatively aged chickens might de-
velop brain amyloid pathology, and have obtained negative 
results. However, our access has been limited to the brains of 
chicken up to 10 years old; these individuals appear to be too 
young to develop amyloid deposits, since the chicken 
lifespan reaches approximately 30 years [34]. In fact, the 
brains of 10-year-old chickens do not appear to differ from 
the brains of chickens between 2 and 14 months old. 
THE DOG 
  The dog has been pointed out as an especially appropriate 
model for the study of human brain aging and neurodegen-
erative diseases. The numerous domestic dog breeds exhibit 
greater diversity in body size than any other terrestrial verte-
brate, and geneticists are taking advantage of this diversity to 
investigate the genetic basis of size and its relationship to 
lifespan [35-37]. Canines have evolved phylogenetically in 
close proximity to humans, making them unusually skilled at 
reading human social and communicative behavior— even 
more so than our nearest primate relatives [38, 39]. Provided 
that ethical normative is enforced, individuals of every age 
are available for study among the immense population of pet 
dogs. Canine neurology, including behavioral medicine, is 
state of the art among veterinary clinical sciences, and access 
to longitudinal records is already possible in many cases [40, 
41]. Dogs  are frequently used for the preclinical develop-
ment of a wide variety of drugs (see for example [42, 43]). 
Regarding AD, almost every current treatment strategy has 
been tried out in the dog, from cholinergic agonists to anti-
oxidant and mitochondrial enzymatic cofactors [44-49]. In-
creasing interest in this model is based on the fact that the 
dog may naturally develop an age-related cognitive dysfunc-
tion that reproduces several aspects of AD [47, 50-53]. Thus, 
numerous studies with dog cohorts that were submitted to 
several behavioral paradigms have revealed subsets of aged 
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dogs that had learning and memory impairments [46, 54-57]. 
This cognitive damage correlated with the extent of A de-
posits in the cerebral cortex [58-60]. Interestingly, a similar 
correlation has been reported in domestic pet dogs, based on 
cognitive status evaluated from questionnaires that were an-
swered by their caregivers [61-63]. Most of these tests for 
evaluation of the cognitive status assess four main behav-
ioural categories: disorientation (on daily walks or at home), 
interaction with owners (lost of interest in greeting or play-
ing; lost of response to incitation), sleep/awake cycle (wan-
der and/or bark during night) and lost of the house training 
habits. It has been reported that 28% of 11-12 year old dogs 
present impairments in one or more of these categories, of 
which 10% have impairments in two or more categories and 
are considered severely impaired. Among 15-16 year old 
dogs, 68% have impairment in one or more category, of 
which 35% have impairments in two or more categories [64, 
65]. 
  Histopathological studies on this putative canine model 
of AD showed that the earliest and more consistently af-
fected areas were in the prefrontal cortex, including the 
gyrus proreus and the hippocampus [59, 66, 67]. Deposition 
of A in the dog appears to progress from deep to superficial 
cortical layers, and from diffuse patches to denser and bet-
ter-delimited plaques [68]. However, dense core neuritic 
plaques and neurofibrillary tangles have not been consis-
tently demonstrated in the dog [69-72]. A deposits do not 
appear in every aged dog, as might be expected if they were 
merely a consequence of normal aging (Fig. 1A-C). Instead, 
as occurs in humans, exogenous and/or genetic factors may 
determine the susceptibility of individual dogs toward devel-
oping amyloid pathology at a given age [73, 74]. Neverthe-
less, in a recent study we have found A angiopathy and a 
moderate to heavy A burden in two aged dogs, although 
they have no apparent cognitive symptoms. This finding is 
reminiscent of similar reports of extensive A deposits in 
human brains that had not been diagnosed with dementia 
(reviewed by [75]). It poses the possibility that, as occurs in 
AD, the development of neuropathological lesions may pre-
cede apparent clinical symptoms by a long period of time in 
the dog. The availability of biomarkers and more refined 
neuropsychological tests in veterinary clinics may enable the 
definition of a canine model for mild cognitive impairment 
in the near future. 
  We have recently found that the canine is also a suitable 
AD model from the molecular point of view, because APP 
and most of the enzymatic machinery for its processing bear 
extensive homology between dogs and humans (GenBank 
accessions AY926579 for APP770, AY926580 for APP751, 
AY926581 for APP714, AY926582 for APP695, AY926587 
for ApoE, AY926590 for presenilin-1, AY926591 for prese-
nilin-2, AY926592 for BACE, AY926593 for ADAM-10, 
AY926594 for ADAM-17 and AY926595 for pleckstrin). In 
particular, the amino acid sequence of A1-42 is identical in 
dogs and humans, whereas in rats and mice it differs from 
the human sequence by three amino acids [26]. Furthermore, 
the profile of the various shorter A peptides found by mass 
spectrometry in the canine LCR is almost identical to that 
found in humans, and both present substantial differences 
when compared to rats and mice [19]. Thus, the study of 
both APP and A peptide processing in the dog could help174    Current Alzheimer Research, 2009, Vol. 6, No. 2  Sarasa and Pesini 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1A-G). The canine model of Alzheimer’s disease. 
(A-C) Cortical A pathology in the dog. (A) Brain section from a 13 years old Pekinese dog without A deposits and (B-C) from a 20 years 
old individual of the same breed with extensive A deposits. The three sections were stained in the same batch with 6E10 monoclonal anti-
body (Signet Lab. Dedham, USA). The level of B and C section is marked over the lateral view of the brain (inset). The earliest and more 
consistently affected areas in the dog were the prefrontal cortex, including the gyrus proreus (GP), the entorhinal cortex (ER) and the hippo-
campus (HP). However in severe cases as the one shown here (B and C), amyloid deposits spread throughout the cortex and can be found also 
in the caudate (arrowheads) and the claustrum (CL). (D-E) the anatomical distribution of the neurons expressing the low affinity nerve growth 
factor receptor (p75
NTR) in the basal forebrain of the dog. Section in D is at the level of the vertical and horizontal diagonal band (BDv and 
BDh, respectively); section in E is at the level of the dorsal and ventral subdivision of the intermediate part of nucleus basalis of Meynert 
(NBid and NBiv, respectively). Framed area in D and E are enlarged in the corresponding inset. (F) Double immunofluorescence staining 
showing that practically all magnocellular cholinergic neurons (red staining) in the basal forebrain co-express p75
NTR (green staining). (G) 
Co-expression of choline acetyl transferase (ChAT, red immunofluorescence) and NADPH-D (blue staining, bright field illumination) in most 
(~80%) of the basal magnocellular neurons in the anterior and intermediate parts of the dog (NBa and NBi respectively; yellow arrows). 
These images were presented at the 17th ECVIM-CA congress and 9th ESVCP congress. Budapest, September 2007. (Suárez M-L, Insua D, 
Corredoira A, Bernedo V, Santamarina G, and Pesini P. The basal forebrain cholinergic neurons in aged dogs with and without cortical amy-
loid pathology).  Natural Non-Trasgenic Animal Models for Research in Alzheimer’s Disease  Current Alzheimer Research, 2009, Vol. 6, No. 2    175 
 
us to understand their biological function and relevance to 
AD, contributing results more reliably translatable to humans 
than those obtained using transgenic mice. The dog has also 
been used in immunotherapeutic assays against fibrillar A, 
and to confirm observational data in humans that combining 
an antioxidant-enriched diet and behavioral enrichment (in-
cluding social, physical, and cognitive components) can lead 
to substantial improvements in cognition and reduced brain 
pathology [47, 76]. 
  However, a pitfall for a more extended use of the dog is 
the dearth of neuroanatomical data regarding the organiza-
tion, normal aging process, and response to pathological ag-
ing of the main neurotransmitter systems implicated in AD. 
We have begun to study this issue and have made a number 
of relevant findings. The cytoarchitectural characteristics of 
the basal forebrain cholinergic neurons in the dog are similar 
to those of humans, as are several relevant phenotypic char-
acteristics of these neurons, including their expression of 
NOS, calbindin D-28K, and p75
NTR nerve growth factor re-
ceptor (Fig. 1D-G) [77]. As has been found in AD brains, the 
number of A6-A7 noradrenergic neurons in the dog shows a 
negative correlation with the extension of cortical A depos-
its as measured in the gyrus proreus [78]. 
  The investigation of brain aging in the dog also deserves 
attention from a veterinary point of view. As in the case of 
human medical technologies, improvements in veterinary 
medicine and husbandry have contributed to lengthening the 
lifespan of our domestic animals, with the unwanted side 
effect of a greater incidence of age-related neurodegenerative 
diseases [44]. The modern society requires more attention to 
the welfare of pet animals, increasingly considered as actual 
“family members”, and there is a growing demand for atten-
tion and treatment of these pet dogs’ age related diseases. 
PRIMATES AND DOLPHINS 
  Primates, like dogs, are among the few animal species 
demonstrating age-dependent brain pathologies resembling 
AD [79-82]. An important advantage of several primate 
models, but not all [80], is that they show AD-like tau-
pathology accounting for a more complete disease model. 
More over, some of these species have relatively short life 
span as for example the mouse lemur (Microcebus murinus) 
which is considered to be elderly over 5 years of age. Inter-
estingly, among elderly mouse lemurs approximately 20% 
develop massive brain atrophy, abundant amyloid plaques, 
cytoskeletal Tau pathology and loss of cholinergic neurons 
[83]. Furthermore, recently it has been documented the first 
case of tauopathy with paired helical filaments, ultrastructur-
ally indistinguishable from those seen in Alzheimer's dis-
ease, in an aged chimpanzee (Pan troglodytes) [84]. Patho-
logic forms of tau were histologically identified in neuronal 
somata, neuropil threads, and plaque-like clusters of neurites 
throughout the neocortex of this animal. Nevertheless,  ac-
cumulation of the abnormally phosphorylated tau protein in 
the brains of animals has been less study than the formation 
of A deposits. Age-related neurofibrillary changes were 
described in sheep and goat in the absence of A [85-87] and 
in wolverine (Gulo gulo) [88], polar bear [89] and dog [72] 
in the presence of A. Thus, non-primate species develop 
age-related cytoskeletal abnormalities similar to those occur-
ring in humans. However to define an operative model from 
these species is hampered by which appear to be species spe-
cific variations in the process of phosphorylation and cleav-
age of tau protein. This, together with their phylogenetic 
proximity to humans, would make primates ideal experimen-
tal models (for example, leading studies in immunotherapy 
are currently being carried out in these species) [90, 91]. 
However, their use is extremely limited for most laboratories 
because of high price, restricted availability, maintenance 
requirements, and ethical considerations. 
  Other animals that may suffer brain pathology resem-
bling AD are cetaceans. Some cetacean species like dolphins 
have extended life spans, could be accessible in determined 
circumstances, and might be useful models to analyze some 
aspects of the disease. We recently hypothesized that the 
coastal beaching of these animals could be related to cogni-
tive impairments of the aged individuals (occasionally fol-
lowed by herds of younger specimens) that might present 
with A deposits or other AD like neuropathological fea-
tures. In tissue samples from stranded dolphins, we have 
found extensive Congo red positive A-immunolabeled de-
posits throughout the brain, including the cerebellum and the 
medulla oblongata where such deposits have only been re-
ported in the more severe AD cases
2. In addition, we have 
found high amino acidic homology between the APP, 
BACE, presenilin-1, and presenilin-2 in various dolphin spe-
cies and their corresponding human counterpart (GeneBank 
entries: AY926583, AY926588, AY926589, AY926584, 
AY926586 and AY926585); in particular, the A1-42 pep-
tide in the three dolphin species that have been studied so far 
(Grampus griseus, Stenella coeruleoalba and Tursiops trun-
catus) was 100% identical to the human peptide. 
CONCLUDING REMARKS 
  There are a variety of species that can serve as experi-
mental models for AD research. In addition to numerous 
transgenic mouse lines, which have proven to be powerful 
tools to aid in understanding various aspects of the disease, 
there are other species that can serve as ‘natural’ wild-type 
models to shed light on different psychopathological mecha-
nisms or even to try new therapeutic strategies. Among these 
natural models we emphasize the chick embryo to assay 
molecules that act on APP metabolism, and the canine model 
specifically to study the first phase of the disease and to test 
new therapies. Dogs have a relatively long lifespan (12-20 
years depending on the breed), share our environment, and 
their behavior and clinical state are easier to explore than 
those of other species. Furthermore, canine APP is identical 
(98%) to the human counterpart, and dogs are the most ac-
cessible among the few animal species demonstrating age-
dependent brain pathology and clinical correlates resembling 
AD. 
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